{"id":"desoximetasone","rwe":[{"pmid":"41730175","year":"2026","title":"Drugs for atopic dermatitis.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"41217063","year":"2025","title":"Exosome-Based Therapy: A Comparative Study of Adipose- and Umbilical Cord-Derived Mesenchymal Stem Cells-Derived Exosomes in Psoriatic Mouse Model.","finding":"","journal":"Experimental dermatology","studyType":"Clinical Study"},{"pmid":"40209307","year":"2025","title":"Sakuranetin modulates IL-17A-related inflammation and enhances skin barrier function in an imiquimod-induced psoriasis model.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"39449424","year":"2024","title":"Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.","finding":"","journal":"Journal of xenobiotics","studyType":"Clinical Study"},{"pmid":"39193096","year":"2024","title":"Familial Reactive Perforating Collagenosis with Adolescence-Onset: A Rare Case Report and Literature Review.","finding":"","journal":"Clinical, cosmetic and investigational dermatology","studyType":"Clinical Study"}],"_fda":{"id":"854be77b-2a59-4141-a411-7931a2a63304","set_id":"0e72952e-8e9f-467a-8191-2bc157087d60","openfda":{"nui":["N0000175576","N0000175450"],"unii":["4E07GXB7AU"],"route":["TOPICAL"],"rxcui":["197574"],"spl_id":["854be77b-2a59-4141-a411-7931a2a63304"],"brand_name":["Desoximetasone"],"spl_set_id":["0e72952e-8e9f-467a-8191-2bc157087d60"],"package_ndc":["50090-5571-0"],"product_ndc":["50090-5571"],"generic_name":["DESOXIMETASONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DESOXIMETASONE"],"pharm_class_epc":["Corticosteroid [EPC]"],"pharm_class_moa":["Corticosteroid Hormone Receptor Agonists [MoA]"],"manufacturer_name":["A-S Medication Solutions"],"application_number":["ANDA073193"],"original_packager_product_ndc":["51672-1270"]},"version":"7","warnings":["WARNINGS Keep out of reach of children."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone cream USP, 0.25% and 15 to 150 times the human dose of desoximetasone cream USP, 0.05%, or desoximetasone gel USP, 0.05%. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time."],"overdosage":["OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS )."],"description":["DESCRIPTION Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% contain the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Each gram of desoximetasone cream USP, 0.05% contains 0.5 mg of desoximetasone in an emollient cream base consisting of cetostearyl alcohol, edetate disodium, isopropyl myristate, lanolin alcohol, mineral oil, purified water, and white petrolatum. Each gram of desoximetasone cream USP, 0.25% contains 2.5 mg of desoximetasone in an emollient cream base consisting of cetostearyl alcohol, isopropyl myristate, lanolin alcohol, mineral oil, purified water, and white petrolatum. Each gram of desoximetasone gel USP, 0.05% contains 0.5 mg of desoximetasone in a gel base consisting of carbomer 940, docusate sodium, edetate disodium, isopropyl myristate, purified water, SDAG-3 95% alcohol, and trolamine. The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11ß,16α)-. Desoximetasone has the molecular formula C 22 H 29 FO 4 and a molecular weight of 376.47. The CAS Registry Number is 382-67-2. The structural formula is: Chemical Structure"],"precautions":["PRECAUTIONS General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure. Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids. Local Adverse Reactions with Topical Corticosteroids Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible. Allergic Contact Dermatitis with Topical Corticosteroids Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing. Concomitant Skin Infections Concomitant skin infections should be treated with an appropriate antimicrobial agent. If the infection persists, desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05% should be discontinued until the infection has been adequately treated. Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. Patients should report any signs of local adverse reactions, especially under occlusive dressings. Other corticosteroid-containing products should not be used with desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05% without first consulting with the physician. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, contact the physician. Laboratory Tests The following tests may be helpful in evaluating the hypothalamic-pituitary-adrenal (HPA) axis suppression: Urinary free cortisol test ACTH stimulation test Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Desoximetasone was nonmutagenic in the Ames test. Pregnancy Teratogenic Effects Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone cream USP, 0.25% and 15 to 150 times the human dose of desoximetasone cream USP, 0.05%, or desoximetasone gel USP, 0.05%. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients."],"how_supplied":["HOW SUPPLIED Product: 50090-5571 NDC: 50090-5571-0 15 g in a TUBE / 1 in a CARTON"],"pediatric_use":["Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients."],"effective_time":"20231209","nursing_mothers":["Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman."],"laboratory_tests":["Laboratory Tests The following tests may be helpful in evaluating the hypothalamic-pituitary-adrenal (HPA) axis suppression: Urinary free cortisol test ACTH stimulation test"],"pharmacokinetics":["Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. Pharmacokinetic studies in men with desoximetasone cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%) and no detectable level (limit of sensitivity: 0.005 μg/mL) in the blood when it was applied topically on the back followed by occlusion for 24 hours. Seven days after application, no further radioactivity was detected in urine or feces. The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester."],"adverse_reactions":["ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies the incidence of adverse reactions were low (0.8%) for desoximetasone cream USP, 0.25%, and included burning, folliculitis, and folliculo-pustular lesions. The incidence of adverse reactions were also 0.8% for desoximetasone cream USP, 0.05% and included pruritus, erythema, vesiculation, and burning sensation. The incidence of adverse reactions for desoximetasone gel USP, 0.05% was 0.3% with one subject reporting stinging and burning at the site of application."],"contraindications":["CONTRAINDICATIONS Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."],"precautions_table":["<table width=\"90%\" styleCode=\"Noautorules\"><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"75%\" align=\"left\" valign=\"top\"/><tbody><tr><td/><td>Urinary free cortisol test</td></tr><tr><td/><td>ACTH stimulation test</td></tr></tbody></table>"],"general_precautions":["General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure. Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids."],"teratogenic_effects":["Teratogenic Effects Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone cream USP, 0.25% and 15 to 150 times the human dose of desoximetasone cream USP, 0.05%, or desoximetasone gel USP, 0.05%. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. Pharmacokinetic studies in men with desoximetasone cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%) and no detectable level (limit of sensitivity: 0.005 μg/mL) in the blood when it was applied topically on the back followed by occlusion for 24 hours. Seven days after application, no further radioactivity was detected in urine or feces. The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester."],"indications_and_usage":["INDICATIONS AND USAGE Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."],"laboratory_tests_table":["<table width=\"90%\" styleCode=\"Noautorules\"><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"75%\" align=\"left\" valign=\"top\"/><tbody><tr><td/><td>Urinary free cortisol test</td></tr><tr><td/><td>ACTH stimulation test</td></tr></tbody></table>"],"information_for_patients":["Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. Patients should report any signs of local adverse reactions, especially under occlusive dressings. Other corticosteroid-containing products should not be used with desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05% without first consulting with the physician. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, contact the physician."],"spl_unclassified_section":["For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only","Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1 Dist. by: Taro Pharmaceuticals U.S.A., Inc. , Hawthorne, NY 10532 Revised: October, 2014 PK-6352-4 89 1014-4"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Apply a thin film of desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05% to the affected skin areas twice daily. Rub in gently."],"spl_product_data_elements":["Desoximetasone Desoximetasone DESOXIMETASONE DESOXIMETASONE cetostearyl alcohol isopropyl myristate lanolin alcohols mineral oil water petrolatum"],"package_label_principal_display_panel":["DESOXIMETASONE Label Image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Desoximetasone was nonmutagenic in the Ames test."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"ANXA1","category":"gene"},{"label":"D07AC03","category":"atc"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Emulsion","category":"form"},{"label":"Gel","category":"form"},{"label":"Ointment","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Atopic dermatitis","category":"indication"},{"label":"Contact dermatitis","category":"indication"},{"label":"Discoid lupus erythematosus","category":"indication"},{"label":"Eruption of skin","category":"indication"},{"label":"Granuloma annulare","category":"indication"},{"label":"Lichen simplex chronicus","category":"indication"},{"label":"Taro","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"9774 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"8817 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"8635 reports"},{"date":"","signal":"ALOPECIA","source":"FDA FAERS","actionTaken":"8121 reports"},{"date":"","signal":"RHEUMATOID ARTHRITIS","source":"FDA FAERS","actionTaken":"8064 reports"},{"date":"","signal":"SYSTEMIC LUPUS ERYTHEMATOSUS","source":"FDA FAERS","actionTaken":"7966 reports"},{"date":"","signal":"PEMPHIGUS","source":"FDA FAERS","actionTaken":"7742 reports"},{"date":"","signal":"ABDOMINAL DISCOMFORT","source":"FDA FAERS","actionTaken":"7697 reports"},{"date":"","signal":"GLOSSODYNIA","source":"FDA FAERS","actionTaken":"7510 reports"},{"date":"","signal":"SWELLING","source":"FDA FAERS","actionTaken":"7041 reports"}],"commonSideEffects":[{"effect":"burning, folliculitis, and folliculo-pustular lesions","drugRate":"0.8%","_validated":true,"placeboRate":""},{"effect":"pruritus, erythema, vesiculation, and burning sensation","drugRate":"0.8%","_validated":true,"placeboRate":""},{"effect":"stinging and burning at the site of application","drugRate":"0.3%","_validated":true,"placeboRate":""}],"contraindications":["Atrophoderma","Hypopituitarism","Peripheral vascular disease"],"specialPopulations":{"Lactation":"It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Because many drugs are excreted in human milk, caution should be exercised when Desoximetasone Topical Spray is administered to nursing woman.","Pregnancy":"Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration at doses to 30 times the human dose of Desoximetasone Topical Spray based on body surface area comparison.","Geriatric use":"Clinical studies of Desoximetasone Cream USP, 0.05%; Desoximetasone Cream USP, 0.25% and Desoximetasone Gel USP, 0.05% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.","Paediatric use":"Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced Hypo-thalamic-pituitary-adrenal (HPA) axis suppression and Cushings syndrome than mature patients because of larger skin surface area to body weight ratio."}},"trials":[],"aliases":[],"company":"Taro","patents":[{"type":"Formulation","number":"8715624","applicant":"SUN PHARMA CANADA INC","territory":"US","tradeName":"TOPICORT","expiryDate":"2026-05-26"},{"type":"Formulation","number":"8277780","applicant":"SUN PHARMA CANADA INC","territory":"US","tradeName":"TOPICORT","expiryDate":"2028-09-01"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.6267/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$594","description":"DESOXIMETASONE 0.05% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DESOXIMETASONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:33:31.606040+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:33:31.605031+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:33:38.347396+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:33:30.242639+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESOXIMETASONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:33:39.028844+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:29.025564+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:29.025626+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:29.025640+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:33:40.685685+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:33:39.747170+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1766/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:33:39.649191+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In co","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:55.040803+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA073193","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:29.025649+00:00"}},"allNames":"topicort","offLabel":[],"synonyms":["desoximetasone","deoxymethasone","desoximethasone","desoxymetasone","desoxymethasone"],"timeline":[{"date":"1977-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from TARO PHARMS NORTH to Taro"},{"date":"1977-02-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Taro Pharms North)"},{"date":"1982-03-29","type":"positive","source":"FDA Orange Book","milestone":"Topicort approved — 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1983-09-30","type":"positive","source":"FDA Orange Book","milestone":"Topicort approved — 0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1985-01-17","type":"positive","source":"FDA Orange Book","milestone":"Topicort approved — 0.05%"},{"date":"1998-04-01","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"},{"date":"2013-04-11","type":"positive","source":"FDA Orange Book","milestone":"Topicort approved — 0.25%"}],"aiSummary":"Topicort, also known as desoximetasone, is a topical spray used to treat conditions such as psoriasis, plaque psoriasis, and scalp psoriasis. It works as a glucocorticoid receptor agonist, a type of small molecule that activates the glucocorticoid receptor.","approvals":[{"date":"1977-02-28","orphan":false,"company":"TARO PHARMS NORTH","regulator":"FDA"}],"brandName":"Topicort","ecosystem":[{"indication":"Atopic dermatitis","otherDrugs":[{"name":"abrocitinib","slug":"abrocitinib","company":"PFIZER Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"}],"globalPrevalence":204050000},{"indication":"Contact dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":324000000},{"indication":"Discoid lupus erythematosus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":2400000},{"indication":"Eruption of skin","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":null},{"indication":"Granuloma annulare","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":null},{"indication":"Lichen simplex chronicus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null},{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"alefacept","slug":"alefacept","company":"Astellas"},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"}],"globalPrevalence":125000000},{"indication":"Primary cutaneous T-cell lymphoma","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"ANXA1","source":"DrugCentral","target":"Annexin A1","protein":"Annexin A1"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid [EPC]","explanation":"","oneSentence":"","technicalDetail":"Topicort is a synthetic glucocorticoid that binds to the glucocorticoid receptor (GR), a transcription factor that regulates the expression of genes involved in inflammation. By activating the GR, Topicort suppresses the production of pro-inflammatory cytokines and chemokines, leading to a reduction in inflammation and immune response."},"commercial":{"launchDate":"1977","_launchSource":"DrugCentral (FDA 1977-02-28, TARO PHARMS NORTH)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/819","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DESOXIMETASONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESOXIMETASONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:35:38.621831","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:33:57.602563+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"fluocinolone acetonide","drugSlug":"fluocinolone-acetonide","fdaApproval":"1963-02-15","patentExpiry":"Nov 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fludroxycortide","drugSlug":"fludroxycortide","fdaApproval":"1963-03-19","relationship":"same-class"},{"drugName":"fluocinonide","drugSlug":"fluocinonide","fdaApproval":"1971-06-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"budesonide","drugSlug":"budesonide","fdaApproval":"1994-02-14","patentExpiry":"Sep 9, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diflorasone diacetate","drugSlug":"diflorasone-diacetate","fdaApproval":"1977-09-14","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mometasone furoate","drugSlug":"mometasone-furoate","fdaApproval":"1987-04-30","patentExpiry":"Oct 3, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-class"},{"drugName":"hydrocortisone aceponate","drugSlug":"hydrocortisone-aceponate","fdaApproval":"","relationship":"same-class"},{"drugName":"fluticasone furoate","drugSlug":"fluticasone-furoate","fdaApproval":"2007-04-27","patentExpiry":"Oct 15, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fluticasone propionate","drugSlug":"fluticasone-propionate","fdaApproval":"1990-12-14","patentExpiry":"Sep 26, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prednicarbate","drugSlug":"prednicarbate","fdaApproval":"1991-09-23","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"difluprednate","drugSlug":"difluprednate","fdaApproval":"2008-06-23","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ulobetasol propionate","drugSlug":"ulobetasol-propionate","fdaApproval":"1990-12-17","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"desoximetasone","indications":{"approved":[{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Taro","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-class"},{"drugId":"fluocinolone-acetonide","brandName":"fluocinolone acetonide","genericName":"fluocinolone acetonide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fludroxycortide","brandName":"fludroxycortide","genericName":"fludroxycortide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fluocinonide","brandName":"fluocinonide","genericName":"fluocinonide","approvalYear":"1971","relationship":"same-class"},{"drugId":"budesonide","brandName":"budesonide","genericName":"budesonide","approvalYear":"1994","relationship":"same-class"},{"drugId":"diflorasone-diacetate","brandName":"diflorasone diacetate","genericName":"diflorasone diacetate","approvalYear":"1977","relationship":"same-class"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-class"},{"drugId":"mometasone-furoate","brandName":"mometasone furoate","genericName":"mometasone furoate","approvalYear":"1987","relationship":"same-class"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-class"},{"drugId":"hydrocortisone-aceponate","brandName":"hydrocortisone aceponate","genericName":"hydrocortisone aceponate","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02985736","phase":"PHASE4","title":"Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2016-09","conditions":["Psoriasis"],"enrollment":20,"completionDate":"2017-01-27"},{"nctId":"NCT02983981","phase":"PHASE4","title":"Topical Psoriasis Study for Patients Receiving Biologic Therapy","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2016-03","conditions":["Psoriasis"],"enrollment":20,"completionDate":"2016-10"},{"nctId":"NCT02340169","phase":"PHASE4","title":"Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-01-23","conditions":["Plaque Psoriasis"],"enrollment":129,"completionDate":"2021-11-22"},{"nctId":"NCT03050294","phase":"PHASE4","title":"Evaluating Treatment Resistant Dermatitis TaroIIR","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-02-01","conditions":["Atopic Dermatitis","Psoriasis"],"enrollment":24,"completionDate":"2017-06-01"},{"nctId":"NCT02595073","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-09-04","conditions":["Atopic Dermatitis"],"enrollment":124,"completionDate":"2017-08-29"},{"nctId":"NCT01206387","phase":"PHASE3","title":"Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2010-08","conditions":["Psoriasis"],"enrollment":120,"completionDate":"2011-01"},{"nctId":"NCT02749656","phase":"PHASE3","title":"Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis","status":"UNKNOWN","sponsor":"Siriraj Hospital","startDate":"2016-01-01","conditions":["Scalp Psoriasis"],"enrollment":105,"completionDate":"2018-12"},{"nctId":"NCT01018134","phase":"PHASE2","title":"Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2009-11","conditions":["Psoriasis"],"enrollment":151,"completionDate":"2010-05"},{"nctId":"NCT01206660","phase":"PHASE3","title":"Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2010-08","conditions":["Psoriasis"],"enrollment":120,"completionDate":"2011-01"},{"nctId":"NCT01043393","phase":"PHASE2","title":"Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2010-02","conditions":["Psoriasis"],"enrollment":24,"completionDate":"2010-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream, Emulsion, Gel, Ointment","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"Desoximetasone"},{"form":"CREAM","route":"TOPICAL","productName":"Topicort"},{"form":"CREAM","route":"TOPICAL","productName":"desoximetasone"},{"form":"CREAM","route":"TOPICAL","productName":"DESOXIMETASONE 0.05% / NIACINAMIDE 4%"},{"form":"EMULSION","route":"TOPICAL","productName":"DESOXIMETASONE 0.05% / HYDROQUINONE 6% / TRETINOIN 0.05%"},{"form":"GEL","route":"TOPICAL","productName":"Desoximetasone"},{"form":"GEL","route":"TOPICAL","productName":"Topicort"},{"form":"OINTMENT","route":"TOPICAL","productName":"DESOXIMETASONE"},{"form":"OINTMENT","route":"TOPICAL","productName":"Desoximetasone"},{"form":"OINTMENT","route":"TOPICAL","productName":"Desoximetasone Oint 0.05%"},{"form":"OINTMENT","route":"TOPICAL","productName":"Topicort"},{"form":"OINTMENT","route":"TOPICAL","productName":"desoximetasone"},{"form":"OINTMENT","route":"TOPICAL","productName":"Desoximetasone"},{"form":"OINTMENT","route":"TOPICAL","productName":"Topicort"},{"form":"OINTMENT","route":"TOPICAL","productName":"DESOXIMETASONE 0.05% / NIACINAMIDE 4%"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146789","MMSL":"1103","NDDF":"002180","UNII":"4E07GXB7AU","VUID":"4018465","CHEBI":"CHEBI:691037","VANDF":"4018465","INN_ID":"2467","RXNORM":"3255","UMLSCUI":"C0011707","chemblId":"CHEMBL1766","ChEMBL_ID":"CHEMBL1766","KEGG_DRUG":"D03697","DRUGBANK_ID":"DB00547","PUBCHEM_CID":"5311067","SNOMEDCT_US":"387473009","IUPHAR_LIGAND_ID":"7067","MESH_DESCRIPTOR_UI":"D003899"},"formularyStatus":[],"originalProduct":{"form":"CREAM","route":"TOPICAL","company":"Taro Pharmaceuticals U.S.A., Inc.","brandName":"Topicort","isOriginal":true,"marketingStatus":"ANDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1977-","companyName":"Taro Pharms North","relationship":"Original Developer"},{"period":"present","companyName":"Taro","relationship":"Current Owner"}],"publicationCount":87,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"D07AC03","allCodes":["D07AC03","D07XC02"]},"biosimilarFilings":[],"originalDeveloper":"Taro Pharms North","recentPublications":[{"date":"2026 Mar 2","pmid":"41730175","title":"Drugs for atopic dermatitis.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2025 Nov","pmid":"41217063","title":"Exosome-Based Therapy: A Comparative Study of Adipose- and Umbilical Cord-Derived Mesenchymal Stem Cells-Derived Exosomes in Psoriatic Mouse Model.","journal":"Experimental dermatology"},{"date":"2025 May","pmid":"40209307","title":"Sakuranetin modulates IL-17A-related inflammation and enhances skin barrier function in an imiquimod-induced psoriasis model.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2024 Oct 15","pmid":"39449424","title":"Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.","journal":"Journal of xenobiotics"},{"date":"2024","pmid":"39193096","title":"Familial Reactive Perforating Collagenosis with Adolescence-Onset: A Rare Case Report and Literature Review.","journal":"Clinical, cosmetic and investigational dermatology"}],"companionDiagnostics":[],"genericManufacturers":16,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Altana","Cosette","Epic Pharma Llc","Fougera Pharms","Glenmark Pharms Ltd","Lupin","Novel Labs Inc","Padagis Israel","Padagis Us","Pai Holdings Pharm","Rising","Sciegen Pharms","Taro","The J Molner","Zydus Lifesciences"],"status":"approved","companyName":"Taro","companyId":"taro","modality":"Small molecule","firstApprovalDate":"1977","enrichmentLevel":4,"visitCount":2,"regulatoryByCountry":[{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO","brand_name_local":"TOPICORT","application_number":"NDA017856"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":""},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1977-02-28T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-03-29T00:00:00.000Z","mah":"TARO","brand_name_local":"TOPICORT","application_number":"NDA018586"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1983-10-03T00:00:00.000Z","mah":"TARO","brand_name_local":"TOPICORT","application_number":"NDA018763"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1985-01-17T00:00:00.000Z","mah":"TARO","brand_name_local":"TOPICORT","application_number":"NDA018594"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-06-07T00:00:00.000Z","mah":"TARO","brand_name_local":"TOPICORT","application_number":"ANDA074286"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-07-14T00:00:00.000Z","mah":"TARO","brand_name_local":"TOPICORT","application_number":"ANDA074904"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-12-19T00:00:00.000Z","mah":"TARO","brand_name_local":null,"application_number":"ANDA073193"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-04-11T00:00:00.000Z","mah":"SUN PHARMA CANADA","brand_name_local":"TOPICORT","application_number":"NDA204141"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-20T00:00:00.000Z","mah":"PADAGIS ISRAEL","brand_name_local":null,"application_number":"ANDA077770"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-12-12T00:00:00.000Z","mah":"LUPIN","brand_name_local":null,"application_number":"ANDA208044"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-03-16T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":null,"application_number":"ANDA203787"},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8715624","territory":"US","patent_type":"Formulation","expiry_date":"2026-05-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8277780","territory":"US","patent_type":"Formulation","expiry_date":"2028-09-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"regulatorySummaries":{"US_FDA_approval_27733":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"27733","summary_short":"The FDA granted marketing authorisation to SCIEGEN PHARMS for Topicort on 16 March 2026, under application number ANDA203787.","summary_long":"The FDA approved the manufacturing (CMC) indication for Topicort, a pharmaceutical product, on 16 March 2026. The marketing authorisation holder is SCIEGEN PHARMS. This approval was granted under the standard expedited pathway.","key_points":["Topicort received marketing authorisation from the FDA on 16 March 2026.","The marketing authorisation holder is SCIEGEN PHARMS.","The approval was granted for the manufacturing (CMC) indication under application number ANDA203787."],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA203787"}],"generated_at":"2026-05-18T07:57:32.539Z"}},"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:33:57.602563+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}